HRP20141150T1 - Kombinacijska terapija raka sa hsp90 inhibitornim spojevima - Google Patents

Kombinacijska terapija raka sa hsp90 inhibitornim spojevima Download PDF

Info

Publication number
HRP20141150T1
HRP20141150T1 HRP20141150AT HRP20141150T HRP20141150T1 HR P20141150 T1 HRP20141150 T1 HR P20141150T1 HR P20141150A T HRP20141150A T HR P20141150AT HR P20141150 T HRP20141150 T HR P20141150T HR P20141150 T1 HRP20141150 T1 HR P20141150T1
Authority
HR
Croatia
Prior art keywords
compound
use according
hydroxy
cancer
tautomer
Prior art date
Application number
HRP20141150AT
Other languages
English (en)
Croatian (hr)
Inventor
Ronald K. Blackman
Kevin Paul Foley
David Proia
Original Assignee
Synta Pharmaceuticals Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synta Pharmaceuticals Corp. filed Critical Synta Pharmaceuticals Corp.
Publication of HRP20141150T1 publication Critical patent/HRP20141150T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HRP20141150AT 2009-10-19 2010-10-19 Kombinacijska terapija raka sa hsp90 inhibitornim spojevima HRP20141150T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US27933009P 2009-10-19 2009-10-19
US33577810P 2010-01-11 2010-01-11
EP10768357.5A EP2490688B1 (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds
PCT/US2010/053199 WO2011049946A1 (en) 2009-10-19 2010-10-19 Combination cancer therapy with hsp90 inhibitory compounds

Publications (1)

Publication Number Publication Date
HRP20141150T1 true HRP20141150T1 (hr) 2015-01-30

Family

ID=43218142

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20141150AT HRP20141150T1 (hr) 2009-10-19 2010-10-19 Kombinacijska terapija raka sa hsp90 inhibitornim spojevima

Country Status (21)

Country Link
US (1) US20120245186A1 (OSRAM)
EP (1) EP2490688B1 (OSRAM)
JP (2) JP2013508378A (OSRAM)
KR (1) KR20120093970A (OSRAM)
CN (1) CN102695504A (OSRAM)
AU (1) AU2010308306A1 (OSRAM)
BR (1) BR112012009215A2 (OSRAM)
CA (1) CA2779233A1 (OSRAM)
CY (1) CY1115902T1 (OSRAM)
DK (1) DK2490688T3 (OSRAM)
EA (1) EA022119B1 (OSRAM)
ES (1) ES2526566T3 (OSRAM)
HR (1) HRP20141150T1 (OSRAM)
MX (1) MX2012004577A (OSRAM)
NZ (2) NZ599445A (OSRAM)
PH (1) PH12012500748A1 (OSRAM)
PL (1) PL2490688T3 (OSRAM)
PT (1) PT2490688E (OSRAM)
RS (1) RS53716B1 (OSRAM)
SI (1) SI2490688T1 (OSRAM)
WO (1) WO2011049946A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2618377A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
US8034834B2 (en) 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
US8063083B2 (en) 2006-05-25 2011-11-22 Synta Pharmaceuticals Corp. Method for treating non-Hodgkin's lymphoma
PL2035396T3 (pl) 2006-05-25 2014-10-31 Synta Pharmaceuticals Corp Związki triazolowe modulujące aktywność hsp90
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
WO2010017479A1 (en) * 2008-08-08 2010-02-11 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
EP2323737A2 (en) 2008-08-08 2011-05-25 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
CA2787785C (en) 2010-01-28 2018-03-06 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20120064175A1 (en) * 2010-05-20 2012-03-15 Synta Pharmaceuticals Corp. HSP90 Inhibitors for Treating Non-Small Cell Lung Cancer in Wild-Type EGFR and/or KRAS Patients
US20130172333A1 (en) * 2010-05-20 2013-07-04 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
AU2011255438A1 (en) * 2010-05-20 2013-01-10 Synta Pharmaceuticals Corp. Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds
US20130171105A1 (en) * 2010-05-24 2013-07-04 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
WO2012162293A1 (en) * 2011-05-23 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mek inhibitors
WO2012162372A1 (en) * 2011-05-24 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
WO2012162584A1 (en) * 2011-05-26 2012-11-29 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with chk inhibitors
CA2840986A1 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
US20140286902A1 (en) * 2011-11-02 2014-09-25 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
CA2854188A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
KR102523430B1 (ko) 2014-08-04 2023-04-19 누에볼루션 에이/에스 염증성, 대사성, 종양성 및 자가면역성 질환의 치료에 유용한 피리미딘의 임의적 융합 헤테로시클릴-치환 유도체
MX2018001073A (es) 2015-08-06 2018-06-12 Chimerix Inc Nucleosidos de pirrolopirimidina y analogos de los mismos utiles como agentes antivirales.
CN105237533B (zh) * 2015-10-26 2017-03-22 中国药科大学 四氢吡啶并[4,3‑d]嘧啶类Hsp90抑制剂及其医药用途
WO2019060692A1 (en) 2017-09-21 2019-03-28 Chimerix, Inc. MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES
US11447479B2 (en) 2019-12-20 2022-09-20 Nuevolution A/S Compounds active towards nuclear receptors
UY38994A (es) 2019-12-20 2021-07-30 Nuevolution As Compuestos activos frente a receptores nucleares
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6274171B1 (en) 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
PT1817295E (pt) 2004-11-18 2013-02-18 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
US8034834B2 (en) * 2006-05-25 2011-10-11 Synta Pharmaceuticals Corp. Method for treating proliferative disorders with HSP90 inhibitors
DE102007002715A1 (de) * 2007-01-18 2008-07-24 Merck Patent Gmbh Triazolderivat
WO2008108386A1 (ja) * 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. 医薬組成物
WO2009002321A1 (en) 2007-06-27 2008-12-31 Thomson Licensing Enhancing image quality
AU2008287367B2 (en) * 2007-08-13 2012-02-23 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
CA2840986A1 (en) * 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds

Also Published As

Publication number Publication date
NZ599445A (en) 2014-04-30
JP2013508378A (ja) 2013-03-07
EP2490688B1 (en) 2014-10-08
AU2010308306A1 (en) 2012-05-10
WO2011049946A1 (en) 2011-04-28
PT2490688E (pt) 2014-12-29
CA2779233A1 (en) 2011-04-28
MX2012004577A (es) 2012-06-13
DK2490688T3 (en) 2014-12-08
PH12012500748A1 (en) 2012-10-29
ES2526566T3 (es) 2015-01-13
CN102695504A (zh) 2012-09-26
US20120245186A1 (en) 2012-09-27
HK1175112A1 (en) 2013-06-28
EA201270570A1 (ru) 2012-09-28
PL2490688T3 (pl) 2015-03-31
NZ622713A (en) 2015-07-31
SI2490688T1 (sl) 2015-01-30
BR112012009215A2 (pt) 2019-09-24
EA022119B1 (ru) 2015-11-30
JP2016041715A (ja) 2016-03-31
RS53716B1 (sr) 2015-04-30
KR20120093970A (ko) 2012-08-23
EP2490688A1 (en) 2012-08-29
CY1115902T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
HRP20141150T1 (hr) Kombinacijska terapija raka sa hsp90 inhibitornim spojevima
US20130156755A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US20130171105A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
NZ601774A (en) Substituted diazole and triazole compounds and compositions and methods of use
KR102095429B1 (ko) 핵 수송 조절인자 및 이의 용도
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
WO2008116053A3 (en) Fap-activated chemotherapeutic compounds, and methods of use thereof
US20130331357A1 (en) Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
US20130150385A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
US20140315943A1 (en) Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors
EP2773345A1 (en) Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
JP2013537229A5 (OSRAM)
WO2012162293A1 (en) Combination therapy of hsp90 inhibitory compounds with mek inhibitors
JP2011517457A5 (OSRAM)
JP2017528504A5 (OSRAM)
WO2013067165A1 (en) Combination therapy of hsp90 inhibitors with platinum-containing agents
EP2714033A1 (en) Combination therapy of hsp90 inhibitory compounds with chk inhibitors
JP2014507443A5 (OSRAM)
JP2009513662A5 (OSRAM)
MX2010004176A (es) Derivado de triazol 1,3,5-trisustituido.
WO2012116061A1 (en) Combination therapy of hsp90 inhibitory compounds with radiotherapy
JP2010524937A5 (OSRAM)
MX2017010299A (es) Terapia de combinacion de inhibidores de la proteina de choque termico 90 (hsp90) e inhibidores de muerte programada 1(pd-1) para tratar cancer.
JP2015531373A5 (OSRAM)
WO2005039550A3 (en) Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds